Skip to main content
Frontiers in Molecular Neuroscience logoLink to Frontiers in Molecular Neuroscience
. 2021 May 21;14:665788. doi: 10.3389/fnmol.2021.665788

CircRNA-ceRNA Network Revealing the Potential Regulatory Roles of CircRNA in Alzheimer’s Disease Involved the cGMP-PKG Signal Pathway

Yuan Zhang 1,*, Lili Qian 1, Yingying Liu 2, Ying Liu 1, Wanpeng Yu 3, Yanfang Zhao 4
PMCID: PMC8176118  PMID: 34093124

Abstract

Background: Alzheimer’s disease (AD) is a chronic progressive neurodegenerative disease. The characteristic pathologies include extracellular senile plaques formed by β-amyloid protein deposition, neurofibrillary tangles formed by hyperphosphorylation of tau protein, and neuronal loss with glial cell hyperplasia. Circular RNAs (circRNAs) are rich in miRNA-binding sites (miRNA response elements, MREs), which serve as miRNA sponges or competitive endogenous RNAs (ceRNAs). Although several research groups have identified dysregulated circRNAs in the cerebral cortex of SAMP8 mice or APP/PS1 mice using deep RNA-seq analysis, we need to further explore circRNA expression patterns, targets, functions and the signaling pathways involved in the pathogenesis of AD and in particular the hippocampal circRNA expression profiles in AD.

Methods: We used deep RNA sequencing to investigate circRNA-ceRNA network patterns in the hippocampus of APP/PS1 mice.

Results: In our study, 70 dysregulated circRNAs, 39 dysregulated miRNAs and 121 dysregulated mRNAs were identified between the APP/PS1 group and the wild-type group at 8 months in the hippocampus of the mice. Through correlation analysis, we identified 11 dysregulated circRNAs, 7 dysregulated miRNAs and 8 dysregulated mRNAs forming 16 relationships in the circRNA-miRNA-mRNA regulatory network. Gene ontology (GO) analysis indicated that the dysregulated circRNAs were most enriched in biological metabolic processes. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that the dysregulation of circRNAs was enriched in the cGMP-PKG signaling pathway, cAMP signaling pathway, Hippo signaling pathway, platelet activation, long-term potentiation and axon guidance. In addition, our findings preliminarily verified that the novel_circ_0003012/mmu-miR-298-3p/Smoc2 signaling axis may regulate the pathophysiology of AD by affecting the cGMP-PKG signaling pathway.

Conclusions: These newly identified circRNAs in networks and signaling pathways reveal potential diagnostic or therapeutic targets for AD.

Keywords: Alzheimer’s disease, circRNA, hippocampus, expression profiles, ceRNA

Introduction

Alzheimer’s disease (AD) is a chronic progressive neurodegenerative disease and is the most common type of senile dementia (Tiwari et al., 2019). The main characteristics are memory impairment, cognitive decline, personality change and language impairment, which seriously affect people’s daily lives. However, the pathogenesis of AD has not been fully elucidated. The characteristic pathologies include extracellular senile plaques formed by β-amyloid protein deposition, neurofibrillary tangles formed by hyperphosphorylation of the tau protein, and neuronal loss with glial cell hyperplasia (Wang et al., 2014; Gouras et al., 2015; Wilkins and Swerdlow, 2017).

Circular RNA (circRNA) is a non-coding RNA with a unique covalent closed loop structure. CircRNAs are rich in miRNA-binding sites (miRNA response elements, MREs), which serve as miRNA sponges or competitive endogenous RNAs (ceRNAs) (Lei et al., 2018; Kristensen et al., 2019). Currently, several studies have shown that circRNAs play an important role in the regulation of neurodegenerative diseases via their interaction with disease-associated miRNAs (D’Ambra et al., 2019).

In previous studies, several research groups have identified dysregulated circRNAs in the cerebral cortex of SAMP8 mice or APP/PS1 mice using deep RNA-seq analysis (Zhang et al., 2017; Ma et al., 2019). Other groups have also identified dysregulated circRNAs in the hippocampal tissues of an AD mouse model by circRNA microarray (Huang et al., 2018; Wang et al., 2018). Currently, it is believed that the nerve loss caused by the development of AD is mainly in the cortex and hippocampus. The hippocampus is very important for learning and memory. Changes in the function and structure of the hippocampus are critical for learning and memory, such as long-term potentiation (LTP) and synaptic remodeling (Matsuzaki et al., 2004; Mu and Gage, 2011). Several key molecules influence the generation of new hippocampal neurons in AD, and significant changes in neurogenesis occur earlier than the onset of hallmark lesions or neuronal impairment (Lazarov and Marr, 2010).

Despite these findings, we need to further explore the expression patterns, targets, and functions of circRNAs and the signaling pathways involved in the pathogenesis of AD. Therefore, further research is of great importance. Here, we detected dysregulation of the circRNA-ceRNA profile in the hippocampus of APP/PS1 mice using deep RNA-seq analysis. We performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses to predict the biological roles and potential signaling pathways of these differentially expressed circRNAs. Furthermore, we conducted circRNA-ceRNA network pattern analysis to further explore the potential roles of dysregulated circRNAs in AD pathogenesis. Taken together, our findings may promote a better understanding of the role of circRNAs in the neuropathogenesis of AD.

Materials and Methods

Animals

Eight-month-old APP/PS1 mice and their age-matched wild-type mice were purchased from Model Animal Research Institute of Myhalic (Wuhan, China). The mice were housed two per cage under the standard conditions (12 h light/dark cycle at 25°C and 50 ± 10% relative humidity). We randomly selected nine animals from each group, three animals for RNA-seq, and six animals for Real-time qPCR. Animals administered general anesthesia and then collected hippocampal tissue. Animal care and experimental procedures were implemented according to the document “Guidance Suggestions for Caring for Laboratory Animals” produced by the Ministry of Science and Technology of China in 2006.

RNA Extraction and Qualification

Total RNA was extracted from each hippocampal tissue sample by RNAprep Pure Tissue Kit (TIANGEN BIOTECH, Beijing, China) in accordance with the manufacturer’s instructions.

Using 1% agarose gels to monitor RNA degradation and contamination. Then, using the NanoPhotometer® spectrophotometer to check the RNA purity (IMPLEN, CA, United States) and using Qubit® RNA Assay Kit in Qubit® 2.0 Flurometer to measure the RNA concentration (Life Technologies, CA, United States). Finally, using the RNA Nano 6000 Assay Kit of the Bioanalyzer 2100 system to assess the RNA integrity (Agilent Technologies, CA, United States).

RNA-Seq

Details of the mRNA-seq, miRNA-seq, and circRNA-seq methods are described in Supplementary Materials.

Real-Time qPCR

To validate the RNA-Seq data, we randomly selected 3 of circRNA, miRNA and mRNA for qRT-PCR analysis, respectively. Total RNA was extracted from each hippocampal tissue sample, and then reverse-transcribed into cDNA using PrimeScriptTM RT reagent Kit with gDNA Eraser (Takara, Dalian, China) according to the manufacturer’s instruction.

Real-time quantitative PCR (RT-qPCR) was performed using the SYBR® Premix Ex TaqTM II (Tli RNase H Plus) Kit with a Bio-Rad CFX Manager 3.1 real-time PCR system (CFX96TM Real-Time PCR, Bio-Rad, United States). The relative circRNA and mRNA expression levels were calculated using the 2–ΔΔCt method and were normalized to GAPDH as an endogenous reference transcript. miRNA expression levels were normalized to that of U6. The specific primers for each gene are listed in Supplementary Table 1. Data shown represent the means of three experiments.

GO Annotations and KEGG Pathway Analyses

Gene Ontology (GO) enrichment analysis of differentially expressed genes was conducted by clusterProfiler, an R package for functional classification and enrichment of gene clusters using hypergeometric distribution. KEGG is a database resource for understanding high-level functions and utilities of the biological system1. We used clusterProfiler R package to test the statistical enrichment of aberrantly expressed circRNAs in KEGG pathways. GO and KEGG terms with corrected P-value < 0.05 were considered significantly enrichment of aberrantly expressed circRNAs.

Annotation for CircRNA-miRNA-mRNA Interaction

We have selected the differentially expressed circRNA, miRNA and mRNA that have been identified. CircRNA-miRNA interactions and miRNA-mRNA interactions were predicted with Arraystar’s home-made miRNA target prediction software based on TargetScan2 and miRanda3. The circRNA-miRNA-mRNA network covered two cases: upregulated circRNA-downregulated miRNA-upregulated mRNA, and downregulated circRNA-upregulated miRNA-upregulated mRNA. Then, we constructed circRNA-miRNA-mRNA network using the Cytoscape software V2.7.0 (San Diego, CA, United States).

Statistical Analysis

Statistical analyses were performed using SPSS v16.0 software (SPSS, Inc., Chicago, IL, United States). All data were expressed as the mean ± SEM. p < 0.05 was statistically significant.

Results

Overview of CircRNA-Seq

A total of 514,529,568 raw reads were generated, 255,871,400 for wild-type (WT) mice, and 258,658,168 for APP/PS1 mice. Removed poly(N)-containing, low-quality, and adaptor-containing reads from the raw data, then remained 506,341,272 clean reads including 251,602,810 for wild-type and 254,738,462 for APP/PS1 mice. The high-quality clean data were mapped to the mouse reference sequence by Hisat24 and the unmapped reads were subsequently selected (Pertea et al., 2016). circRNAs were detected and identified using find_circ and CIRI, 5,683 circRNAs were detected (Memczak et al., 2013; Gao et al., 2015). These circRNAs were used for subsequent analyses.

Overview of miRNA-Seq

A total of 90,306,346 raw reads were generated, 42,973,163 for WT mice, and 47,333,183 for APP/PS1 mice. After removal of low-quality and adaptor sequences, 41,501,993 clean reads for WT group and 46,256,666 clean reads for APP/PS1 group were remained. The reads we selected are mostly based on the length of 21–22 nt in both groups. These reads were annotated and classified based on previous studies (Ma et al., 2019). Finally, 1,351 matured miRNAs (1,275 known and 76 novel) were detected. These miRNAs were used for the subsequent analysis.

Overview of mRNA-Seq

A total of 267,484,154 raw reads were generated: 135,704,866 for APP/PS1 mice, and 131,779,288 for wild-type mice. After discarding the reads with adapters, poly-N > 10%, and discarding the low-quality reads. 211,535,266 UMI reads were obtained: 107,820,630 for APP/PS1 mice, and 103,714,636 for wild-type mice. The clean reads were mapped to the mouse reference genome, and the Dedup2MappedUMI rates were approximately 80.50% for APP/PS1 mice and 85.08% for wild-type mice. The cufflink results indicated that 57,077 protein-coding transcripts were identified. These mRNAs were used for the subsequent analysis.

Differential Expression Analysis Between APP/PS1 and Wild-Type Mice

We identified 70 significantly aberrantly expressed circRNAs between APP/PS1 mice and wild-type (WT) mice at 8 months in the hippocampus (p < 0.05), of which 44 circRNAs were upregulated and 26 were downregulated (Table 1). We performed cluster analysis on the differential circRNA expression and generated a heatmap to visualize the results of the cluster analysis (Figures 1A,B).

TABLE 1.

Differently expressed circRNAs between APP/PS1 and WT mice.

Name p-value log2Fold Change circRNA type Chr. Source gene name
Up-regulated
mmu_circ_0001787 0.00010101 2.4893 Exonic chr9 Glce
novel_circ_0001132 0.0002256 2.3685 Intronic chr12 Unc79
novel_circ_0003089 0.0006568 2.079 Exonic chr16 Mapk1
novel_circ_0005088 0.0050106 1.7954 Exonic chr1 Phf3
mmu_circ_0000196 0.0094188 1.6488 Exonic chr10 Ano4
mmu_circ_0001771 0.010104 1.631 Exonic chr9 Cadm1
novel_circ_0007848 0.011021 1.6252 Intronic chr5 Fam193a
novel_circ_0001474 0.011332 1.602 Exonic chr12 Mipol1
novel_circ_0003841 0.015839 1.5111 Intronic chr17 Nrxn1
novel_circ_0005945 0.01807 1.4807 Exonic chr2 Rc3h2
novel_circ_0008954 0.022687 1.4658 Exonic chr7 Gas2
novel_circ_0003498 0.008883 1.4639 Exonic chr17 Telo2
novel_circ_0002016 0.020061 1.4473 Exonic chr13 2210408I21Rik
novel_circ_0003615 0.021294 1.437 Exonic chr17 St6gal2
novel_circ_0001587 0.02155 1.4335 Intronic chr12 Sipa1l1
novel_circ_0000448 0.021844 1.4298 Exonic chr10 Plxnc1
novel_circ_0009294 0.022252 1.4243 Exonic chr8 Pdpr
novel_circ_0002041 0.022454 1.4216 Exonic chr13 Wdr37
novel_circ_0007425 0.022994 1.4151 Exonic chr4 Atg4c
novel_circ_0004431 0.023718 1.4056 Exonic chr19 Slf2
novel_circ_0004837 0.032011 1.3795 Exonic chr1 Dcaf6
novel_circ_0009991 0.030549 1.3331 Exonic chr9 Cdon
novel_circ_0001724 0.034337 1.3294 Exonic chr13 Ipo11
novel_circ_0006435 0.03936 1.3265 Exonic chr3 Miga1
novel_circ_0010591 0.032498 1.3142 Exonic chrX Ctps2
mmu_circ_0000672 0.02096 1.3038 Exonic chr16 Pi4ka
novel_circ_0010561 0.036087 1.2772 Exonic chrX Cnksr2
novel_circ_0009202 0.039016 1.259 Exonic chr7 Picalm
mmu_circ_0001447 0.040307 1.2485 Exonic chr6 Cped1
novel_circ_0003266 0.040406 1.2478 Exonic chr16 Lsamp
mmu_circ_0001023 0.041613 1.2385 Exonic chr2 Tank
novel_circ_0000378 0.04377 1.2224 Exonic chr10 Slc41a2
novel_circ_0003012 0.043524 1.219 Exonic chr15 Adcy6
novel_circ_0002625 0.049801 1.1821 Exonic chr15 Npr3
novel_circ_0003809 0.049842 1.1819 Exonic chr17 Srbd1
novel_circ_0004941 0.033054 1.0292 Exonic chr1 Cdc42bpa
novel_circ_0003234 0.017509 0.79777 Exonic chr16 Stxbp5l
mmu_circ_0001370 0.025479 0.72313 Exonic chr5 Cds1
mmu_circ_0001304 0.040342 0.71604 Exonic chr4 Rere
novel_circ_0006992 0.02793 0.61947 Exonic chr4 Ptp4a2
mmu_circ_0000585 0.036122 0.52692 Exonic chr15 Stk3
mmu_circ_0001125 0.00010971 0.49891 Exonic chr3 Elf2
mmu_circ_0001331 0.0037768 0.45734 Exonic chr5 Ppp1cb
mmu_circ_0001311 0.01803 0.35681 Exonic chr5 Ankib1
Down-regulated
mmu_circ_0000042 0.0011776 −2.0607 Exonic chr1 Plcl1
novel_circ_0006337 0.0071747 −1.6991 Exonic chr3 Tmem56
novel_circ_0007391 0.013014 −1.5984 Exonic chr4 Focad
novel_circ_0007837 0.012984 −1.5635 Exonic chr5 Nsd2
novel_circ_0002311 0.014154 −1.5245 Exonic chr14 Vdac2
novel_circ_0004349 0.017713 −1.4676 Exonic chr19 Btaf1
novel_circ_0000098 0.019977 −1.4339 Exonic chr10 Usp15
novel_circ_0005647 0.028912 −1.4057 Exonic chr2 Ralgapa2
mmu_circ_0000233 0.017241 −1.3738 Exonic chr11 Tns3
novel_circ_0000318 0.032366 −1.3682 Exonic chr10 Arid5b
novel_circ_0008567 0.010996 −1.3302 Intronic chr6 Ctnna2
novel_circ_0009825 0.029543 −1.3182 Exonic chr9 Qrich1
novel_circ_0006299 0.044778 −1.2889 Exonic chr3 Vav3
mmu_circ_0001865 0.022528 −1.2856 Exonic chrX Tspan7
novel_circ_0001016 0.040106 −1.2277 Exonic chr11 Ppm1d
novel_circ_0009273 0.042078 −1.2096 Exonic chr8 Nfatc3
novel_circ_0002029 0.043894 −1.1991 Exonic chr13 Adarb2
novel_circ_0006958 0.043894 −1.1991 Exonic chr4 Zmym4
novel_circ_0005255 0.03522 −1.1883 Exonic chr1 Kansl1l
mmu_circ_0000018 0.03809 −1.1185 Exonic chr1 Rims1
novel_circ_0004254 0.03478 −1.035 Exonic chr19 Trpm3
novel_circ_0010672 0.025091 −0.93642 Exonic chrX
novel_circ_0006686 0.041843 −0.8083 Exonic chr3 Wdr49
mmu_circ_0000717 0.029471 −0.69561 Exonic chr16 Ttc3
mmu_circ_0001076 0.027567 −0.51113 Exonic chr2 Tasp1
mmu_circ_0001336 0.019943 −0.39615 Exonic chr5 Nsd2

FIGURE 1.

FIGURE 1

Expression profiles of distinct RNAs. (A,B) Expression profiles of circRNAs. (A) In the volcano plots, green, red, and blue points represent circRNAs that were downregulated, upregulated, and not significantly different in 8-month APP/PS1 mice relative to 8-month WT mice. (B) Cluster analysis of expression of circRNAs. Red and blue: increased and decreased expression, respectively. (C,D) Expression profiles of miRNAs. (C) In the volcano plots, green, red, and blue points represent miRNAs that were downregulated, upregulated, and not significantly different in 8-month APP/PS1 mice relative to 8-month WT mice. (D) Cluster analysis of expression of miRNAs. Red and blue: increased and decreased expression, respectively. (E,F) Expression profiles of mRNAs. (E) In the volcano plots, green, red, and blue points represent mRNAs that were downregulated, upregulated, and not significantly different in 8-month APP/PS1 mice relative to 8-month WT mice. (F) Cluster analysis of expression of mRNAs. Red and blue: increased and decreased expression, respectively. (G–I) Chromosomal distribution of differentially expressed circRNAs in hippocampal of APP/PS1 mice. (G) Chromosomal localization of differentially expressed circRNAs in hippocampal of APP/PS1 mice. (H) Gene localization of upregulated circRNAs in hippocampal of APP/PS1 mice. (I) Gene localization of downregulated circRNAs in hippocampal of APP/PS1 mice.

Next, we identified 39 significantly aberrantly expressed miRNAs between APP/PS1 mice and WT mice (p < 0.05), of which 16 miRNAs were upregulated and 23 were downregulated (Table 2). Cluster analysis and heatmapping were performed to show the results of the differential miRNA expression (Figures 1C,D).

TABLE 2.

Differently expressed miRNAs between APP/PS1 and WT mice.

Name AD_ readcount Ctrl_ readcount log2FoldChange p-value
Up-regulated
mmu-miR-6481 18.68982 4.322652 1.3238 0.001602
mmu-miR-29b-3p 495.2749 211.0125 1.1645 8.24E-09
mmu-miR-29a-3p 118111.2 54394.02 1.0745 2.69E-10
mmu-miR-344d-3-5p 319.5235 148.8742 0.97566 0.000481
mmu-miR-3074-1-3p 185.8845 102.5404 0.8147 7.04E-05
mmu-miR-29c-3p 139.5045 76.32593 0.7979 0.001251
mmu-miR-24-1-5p 188.332 105.8336 0.78842 0.000132
mmu-miR-129b-5p 2732.962 1536.956 0.78262 0.000131
mmu-miR-3102-3p 962.5197 569.701 0.71115 0.000643
mmu-miR-222-3p 18468.63 11009.11 0.69991 0.000922
mmu-miR-664-3p 1197.966 725.9918 0.68802 0.000265
mmu-miR-221-5p 2240.683 1361.592 0.68249 0.000392
mmu-miR-3068-5p 340.8997 209.7466 0.66796 0.000222
mmu-miR-221-3p 16177.18 10037.58 0.65584 0.00042
mmu-let-7e-3p 405.1511 275.5497 0.53313 0.001513
mmu-miR-344b-3p 1073.644 738.0082 0.52116 0.00206
Down-regulated
mmu-miR-298-5p 333.5885 1352.94 −1.9447 4.46E-31
mmu-miR-1197-3p 4.053018 23.29665 −1.7052 2.61E-05
mmu-miR-1983 392.6913 1361.133 −1.6874 3.13E-16
mmu-miR-412-5p 473.496 1532.112 −1.6259 5.95E-21
mmu-miR-298-3p 2.126654 17.24759 −1.6224 0.000178
mmu-miR-344f-3p 155.3415 482.7177 −1.5446 2.33E-14
mmu-miR-881-3p 4.187014 22.05614 −1.5438 0.000216
mmu-miR-449a-5p 12.80265 50.6019 −1.5218 2.61E-05
mmu-miR-871-3p 9.149676 31.4921 −1.3645 0.000292
mmu-miR-669e-5p 3.739892 16.45383 −1.35 0.001142
mmu-miR-6977-3p 4.825787 22.62498 −1.3302 0.001815
mmu-miR-666-5p 918.8775 2496.094 −1.3144 1.17E-07
mmu-miR-296-3p 126.8954 339.053 −1.2638 3.31E-06
mmu-miR-704 11.4574 33.68301 −1.2305 0.000545
mmu-miR-323-3p 3855.472 8182.974 −1.0241 4.28E-07
mmu-miR-503-3p 34.76984 76.19848 −1.0154 0.000105
mmu-miR-412-3p 108.1681 228.1667 −0.96854 0.000283
mmu-miR-322-3p 262.6622 558.4182 −0.94468 0.001368
mmu-miR-3078-5p 73.46593 127.4599 −0.75059 0.000458
mmu-miR-351-5p 221.2018 378.9669 −0.73994 0.000168
mmu-miR-487b-3p 1994.151 3127.145 −0.62393 0.000249
mmu-miR-467a-5p 901.2772 1233.437 −0.44142 0.001861
mmu-miR-467b-5p 901.2772 1233.437 −0.44142 0.001861

Finally, we estimated the expression levels of the mRNA transcripts. A total of 121 mRNAs were significantly aberrantly expressed between the APP/PS1 mice and the WT mice (p < 0.05), with 34 upregulated mRNAs and 87 downregulated mRNAs (Table 3). Cluster analysis and heatmapping were performed to show the results of the differential mRNA expression (Figures 1E,F).

TABLE 3.

Differently expressed mRNAs between APP/PS1 and WT mice.

Gene_id Readcount_AD Readcount_Ctrl Log2FoldChange p-value Gene name
Up-regulated
ENSMUSG00000081229 59.69713 0 Inf 4.76E-15 Lamr1-ps1
ENSMUSG00000083481 9.956849 0.597699 4.0582 0.0035986 Rps8-ps2
ENSMUSG00000068129 14.61925 0.919661 3.9906 0.00046637 Cst7
ENSMUSG00000097754 8.600735 0.599123 3.8435 0.027421 Ptgs2os2
ENSMUSG00000104674 55.02875 4.59332 3.5826 1.16E-07 Gm42756
ENSMUSG00000098758 10.60356 0.918237 3.5295 0.026071 7630403G23Rik
ENSMUSG00000081738 134.6703 14.72345 3.1932 0.027496 Hmgb1-ps2
Novel01171 13.22348 2.500661 2.4027 0.027206 −//−
Novel01252 27.8467 5.773438 2.27 0.014262
ENSMUSG00000006179 12.82333 3.055696 2.0692 0.030813 Prss16
Novel00437 23.62582 5.769878 2.0338 0.0083936
Novel00379 51.25592 13.7437 1.8989 0.029936
Novel01429 21.80691 6.345889 1.7809 0.033866
ENSMUSG00000096256 27.55918 8.075859 1.7708 0.019005 Gm21093
Novel01018 36.84361 11.54332 1.6744 0.021943 −//−
ENSMUSG00000109588 33.27743 10.43325 1.6734 0.045052 Lnp1
ENSMUSG00000041828 160.808 53.22581 1.5951 0.00079777 Abca8a
ENSMUSG00000024810 659.4621 221.4448 1.5743 0.00051526 Il33
ENSMUSG00000110027 65.12381 22.14243 1.5564 0.012239 C030029H02Rik
ENSMUSG00000079037 28336.45 9928.219 1.5131 0.00021683 Prnp
ENSMUSG00000084159 37.20414 13.89054 1.4214 0.031861 Gm12696
ENSMUSG00000064201 249.4366 93.2043 1.4202 0.0027087 Krt2
ENSMUSG00000027173 50.06709 19.49118 1.361 0.042989 Depdc7
ENSMUSG00000022892 90474.64 35410.63 1.3533 0.010394 App
Novel00624 52.06992 20.71021 1.3301 0.04299 −//−
ENSMUSG00000054986 51.03505 21.26117 1.2633 0.039106 Sec14l3
ENSMUSG00000105891 38.45599 16.56134 1.2154 0.035959 A230001M10Rik
ENSMUSG00000063902 297.1976 131.3646 1.1778 0.028533 Gm7964
ENSMUSG00000095690 44.8563 20.49973 1.1297 0.0425 Rab11b-ps2
ENSMUSG00000069516 93.97817 44.04001 1.0935 0.033869 Lyz2
ENSMUSG00000021732 167.113 81.39735 1.0378 0.042625 Fgf10
ENSMUSG00000062825 13041.13 6475.64 1.01 0.01957 Actg1
ENSMUSG00000020251 240.9446 127.1682 0.92196 0.041038 Glt8d2
ENSMUSG00000067288 392.7952 223.849 0.81125 0.044513 Rps28
Down-regulated
ENSMUSG00000024903 0 7.882801 −Inf 0.0030367 Lao1
ENSMUSG00000053441 0 5.745342 −Inf 0.024105 Adamts19
Novel00685 0.565765 139.4277 −7.9451 1.57E-09 −//−
ENSMUSG00000047773 0.565765 13.41798 −4.5678 0.015067 Ankfn1
ENSMUSG00000118133 0.565765 10.16852 −4.1678 0.006811 AC102268.2
ENSMUSG00000070473 0.516452 7.667856 −3.8921 0.028073 Cldn3
Novel01330 0.516452 7.007228 −3.7621 0.04024
ENSMUSG00000025383 0.774678 10.01955 −3.6931 0.014138 Il23a
ENSMUSG00000035551 7.033407 81.43574 −3.5334 2.10E-07 Igfbpl1
ENSMUSG00000004328 5.915878 53.47947 −3.1763 1.73E-05 Hif3a
ENSMUSG00000115529 7.914695 60.06239 −2.9239 0.0028139 9630013A20Rik
ENSMUSG00000074217 1.955521 13.45871 −2.7829 0.019075 2210011C24Rik
ENSMUSG00000049598 1.746609 11.60482 −2.7321 0.027804 Vsig8
ENSMUSG00000047109 3.934697 24.22868 −2.6224 0.0037399 Cldn14
ENSMUSG00000057606 1.929862 10.4023 −2.4303 0.045634 Colq
ENSMUSG00000027654 9.478051 48.00599 −2.3406 0.021837 Fam83d
ENSMUSG00000051980 2.357676 11.84359 −2.3287 0.008081 Casr
ENSMUSG00000026435 3.037738 14.20985 −2.2258 0.047127 Slc45a3
ENSMUSG00000104494 12.53744 54.5147 −2.1204 0.039037 Gm37111
ENSMUSG00000028661 12.59477 50.02412 −1.9898 0.0053336 Epha8
ENSMUSG00000017697 4.731023 18.54485 −1.9708 0.017823 Ada
ENSMUSG00000029675 51.15106 198.07 −1.9532 0.0003248 Eln
ENSMUSG00000026043 20.30419 77.41927 −1.9309 0.00054551 Col3a1
ENSMUSG00000023153 3.958351 14.95509 −1.9177 0.046526 Tmem52
ENSMUSG00000066407 6.51495 23.67792 −1.8617 0.025408 Gm10263
ENSMUSG00000025270 16.99661 59.72416 −1.8131 0.027639 Alas2
ENSMUSG00000040298 9.491716 32.54046 −1.7775 0.01854 Btbd16
ENSMUSG00000029005 10.42031 34.6719 −1.7344 0.0043488 Draxin
ENSMUSG00000022090 88.96601 287.1362 −1.6904 0.035372 Pdlim2
ENSMUSG00000032278 13.27847 42.62864 −1.6827 0.017123 Paqr5
ENSMUSG00000069917 17.62335 55.95631 −1.6668 0.017287 Hba-a2
ENSMUSG00000027570 195.4526 609.5565 −1.6409 0.0033892 Col9a3
ENSMUSG00000036913 13.19585 40.75662 −1.6269 0.029634 Trim67
ENSMUSG00000026347 85.99188 261.2666 −1.6033 0.030127 Tmem163
ENSMUSG00000015202 40.48648 122.0282 −1.5917 0.003746 Cnksr3
ENSMUSG00000039328 41.31611 121.2591 −1.5533 0.041664 Rnf122
ENSMUSG00000026879 856.6371 2497.441 −1.5437 0.0046071 Gsn
ENSMUSG00000037295 24.41851 70.57507 −1.5312 0.011442 Ldlrap1
ENSMUSG00000021835 19.88039 57.41643 −1.5301 0.016712 Bmp4
ENSMUSG00000052688 16.68903 47.42609 −1.5068 0.017068 Rab7b
ENSMUSG00000079017 8.727027 24.66459 −1.4989 0.034856 Ifi27l2a
ENSMUSG00000027750 12.84297 36.12737 −1.4921 0.01735 Postn
ENSMUSG00000027669 95.09477 264.4664 −1.4756 0.0057058 Gnb4
ENSMUSG00000043903 14.93845 40.98431 −1.456 0.037328 Zfp469
ENSMUSG00000027858 972.4845 2549.279 −1.3903 0.035674 Tspan2
ENSMUSG00000031285 64.95229 169.2304 −1.3815 0.0088063 Dcx
ENSMUSG00000046718 47.23032 122.6923 −1.3773 0.024186 Bst2
ENSMUSG00000083061 26.84117 69.17754 −1.3659 0.027105 Gm12191
ENSMUSG00000076439 604.8117 1557.412 −1.3646 0.038822 Mog
ENSMUSG00000040373 66.88182 169.6338 −1.3427 0.0119 Cacng5
ENSMUSG00000052305 55.29137 137.6412 −1.3158 0.026801 Hbb-bs
ENSMUSG00000049928 22.40201 54.60002 −1.2853 0.04063 Glp2r
ENSMUSG00000095123 23.96537 57.53148 −1.2634 0.043398 Gm21781
ENSMUSG00000038550 56.48149 135.2756 −1.2601 0.020549 Ciart
ENSMUSG00000055415 21.08322 50.34414 −1.2557 0.034212 Atp10b
ENSMUSG00000049721 60.25462 142.5146 −1.242 0.033117 Gal3st1
ENSMUSG00000029661 86.15144 201.1932 −1.2236 0.014912 Col1a2
ENSMUSG00000028655 117.6374 270.6833 −1.2023 0.024522 Mfsd2a
ENSMUSG00000056999 291.2056 665.5641 −1.1925 0.0081406 Ide
ENSMUSG00000061436 173.1805 391.0994 −1.1753 0.035685 Hipk2
ENSMUSG00000029622 149.4121 334.9681 −1.1647 0.019696 Arpc1b
ENSMUSG00000029570 90.59498 200.9065 −1.149 0.035382 Lfng
ENSMUSG00000105987 33.82957 73.99915 −1.1292 0.034879 AI506816
ENSMUSG00000055485 169.7093 370.7928 −1.1275 0.018528 Soga1
ENSMUSG00000054404 72.10059 156.4623 −1.1177 0.038152 Slfn5
ENSMUSG00000022197 300.6014 640.066 −1.0904 0.015608 Pdzd2
ENSMUSG00000038375 876.3089 1862.118 −1.0874 0.036051 Trp53inp2
ENSMUSG00000021903 23.37557 49.0625 −1.0696 0.048392 Galnt15
ENSMUSG00000102234 57.9682 121.1882 −1.0639 0.048061 Gm37885
ENSMUSG00000038173 110.4855 230.3017 −1.0597 0.047454 Enpp6
ENSMUSG00000038059 80.18825 167.0305 −1.0586 0.03448 Smim3
ENSMUSG00000052229 619.3117 1275.477 −1.0423 0.0078224 Gpr17
ENSMUSG00000033685 218.4847 448.8172 −1.0386 0.04342 Ucp2
ENSMUSG00000020661 433.9094 890.5794 −1.0374 0.023838 Dnmt3a
ENSMUSG00000028962 262.8775 538.6218 −1.0349 0.035006 Slc4a2
ENSMUSG00000022096 152.228 311.8075 −1.0344 0.047777 Hr
ENSMUSG00000030168 472.0721 966.8106 −1.0342 0.029204 Adipor2
ENSMUSG00000033209 110.2507 219.8822 −0.99594 0.04941 Ttc28
ENSMUSG00000049791 58.0428 115.4981 −0.99268 0.047269 Fzd4
ENSMUSG00000035104 92.2629 182.6223 −0.98504 0.047666 Eva1a
ENSMUSG00000029086 96.90165 190.6386 −0.97625 0.049665 Prom1
ENSMUSG00000040268 743.4839 1454.211 −0.96786 0.031958 Plekha1
ENSMUSG00000021614 134.8811 257.3204 −0.93188 0.025777 Vcan
ENSMUSG00000030711 51.07835 97.36197 −0.93065 0.043666 Sult1a1
ENSMUSG00000036036 31.18596 57.70265 −0.88774 0.045222 Zfp57
ENSMUSG00000006403 348.0064 602.54 −0.79194 0.048289 Adamts4
ENSMUSG00000040565 264.231 452.6413 −0.77657 0.044065 Btaf1

The data showed that the significantly aberrantly expressed circRNAs were scattered across different chromosomes: the 44 upregulated circRNAs were located on 17 chromosomes, and the 26 downregulated circRNAs were located on 15 chromosomes. The top three chromosomes for the upregulated circRNAs were chromosome (chr.) 5 (4/44), chr. 16 (4/44), and chr. 17 (4/44), while the top two chromosomes for the downregulated circRNAs were chr. 1 (3/26) and chr. 3 (3/26). As for localization of the dysregulated circRNAs, there were 40 exonic and 4 intronic in the upregulated circRNAs and 25 exonic and 1 intronic in the downregulated circRNAs (Figures 1G–I and Table 1).

qPCR Confirmation

We used RT-qPCR to confirm the differentially expressed RNAs in our RNA-seq experiments. We randomly selected three circRNAs, three miRNAs and three mRNAs to perform RT-qPCR. As shown in Figure 2A, all selected transcripts were detected in the hippocampus of the APP/PS1 mice and WT mice and nearly exhibited significant differential expression. In summary, near consistency was observed between the qPCR results and the RNA-seq data.

FIGURE 2.

FIGURE 2

Validation of circRNA, miRNA and mRNAs expression by qPCR. (A) The expression levels of candidate circRNAs, miRNAs and mRNAs for validation by qPCR in hippocampal tissues of 8-month-old APP/PS1 mice and WT mice. (B) The expression levels of candidate circRNAs, miRNAs and mRNAs for validation by qPCR in hippocampal tissues of 8-month-old APP/PS1 mice and 2-month-old APP/PS1 mice. CircRNA and mRNA expression was quantified relative to Gapdh expression level by using the comparative cycle threshold (ΔCT) method. MiRNA expression was quantified relative to U6 expression level by using the comparative cycle threshold (ΔCT) method. Data are presented as means ± SD (n = 6; *p < 0.05). (C) The comparison information of the RNA-Seq and qRT-PCR data of 8-month-old APP/PS1 mice vs. WT mice.

Furthermore, we confirmed the differential expression of circRNAs, miRNAs and mRNAs in 8-month-old APP/PS1 mice relative to 2-month-old APP/PS1 mice. The results showed that mmu_circ_0000672, mmu-miR-344d-3-5p and ENSMUSG00000068129 (Cst7) were significantly different between the hippocampal tissues of 8-month-old APP/PS1 mice and 2-month-old APP/PS1 mice (P < 0.05) (Figure 2B). This result indicated that these genes changed significantly with the age of the APP/PS1 mice.

GO and KEGG Analyses

Gene Ontology (GO) analyses were performed on the circRNAs, and the top highly significantly enriched GO terms of the dysregulated circRNAs on biological process (BP) and molecular function (MF) are shown in Figure 3A. The 5 top terms were phosphorus metabolic process (GO: 0006793), phosphate-containing compound metabolic process (GO: 0006796),

FIGURE 3.

FIGURE 3

(A) Gene Ontology (GO) Enrichment Annotations of pathological progression of AD: Biological Process (BP) and Molecular Function (MF). (B) Significantly Enriched Kyoto Encyclopedia of Genes and Genomes (KEGG). The aberrantly expressed circRNAs in distinct aspects of AD pathology.

organophosphate metabolic process (GO: 0019637), nucleotide metabolic process (GO: 0009117) and nucleoside phosphate metabolic process (GO: 0006753). Several metabolic pathway-related terms were also observed, such as pyrimidine nucleobase metabolic process (GO: 0006206), ribonucleotide metabolic process (GO: 0009259) and ribose phosphate metabolic process (GO: 0019693). In summary, the pathological progression of AD may be associated with several metabolic pathways regulated by circRNAs.

In addition, we also performed GO analysis of miRNAs and mRNAs. Through GO analysis of miRNAs, we found that the 20 top terms enriched in BP, cellular component (CC) and MF were almost all associated with cellular metabolic process, intracellular organelle/part and binding functions (Supplementary Figure 1A): cellular metabolic process (GO: 0044237), metabolic process (GO: 0008152), cellular macromolecule metabolic process (GO: 0044260), intracellular part (GO: 0044424), intracellular organelle (GO: 0043229), membrane-bounded organelle (GO: 0043227), intracellular membrane-bounded organelle (GO:0043231), protein binding (GO:0005515), and binding (GO: 0005488). Moreover, GO analysis indicated that the most enriched mRNAs correlated with single-organism developmental process (GO: 0044767), developmental process (GO: 0032502), multicellular organismal development (GO: 0007275), anatomical structure development (GO: 0048856), system development (GO: 0048731), gliogenesis (GO:0042063), extracellular region (GO: 0005576), extracellular region part (GO: 0044421), extracellular space (GO: 0005615) and structural molecule activity (GO: 0005198) (Supplementary Figure 2A). This result indicated that the dysregulated mRNAs were mostly enriched in the cellular/organism development process or cell differentiation.

Kyoto Encyclopedia of Genes and Genomes pathway analysis was performed to determine the signaling pathways related to the dysregulated circRNAs. By using the Q-value scale from 0 to 1, the top 20 significantly enriched pathways were identified, as shown in Figure 3B. Specifically, the cGMP-PKG signaling pathway, cAMP signaling pathway, axon guidance, platelet activation, LTP, Hippo signaling pathway and phosphatidylinositol signaling system were demonstrated to be closely related to the onset and development of AD.

Kyoto Encyclopedia of Genes and Genomes pathways were associated with dysregulated miRNAs involved in the MAPK signaling pathway, Ras signaling pathway, endocytosis, focal adhesion, axon guidance, neurotrophin signaling pathway and glycerophospholipid metabolism (Supplementary Figure 1B). KEGG pathway analysis of the dysregulated mRNAs identified enrichment in metabolic pathways, protein digestion and absorption, ribosomes, regulation of actin cytoskeleton, PI3K-Akt signaling pathway, platelet activation, spliceosome, tight junction, and the Hippo signaling pathway (Supplementary Figure 2B).

Construction of the CircRNA-ceRNA Regulatory Networks

CircRNAs have MREs, which can be used as miRNA sponges to competitively bind miRNAs, thereby inhibiting miRNA targets to mRNA and indirectly regulating mRNA expression. Based on ceRNA theory, to search for circRNA-miRNA-gene pairs with the same MREs, circRNA-miRNA-gene pairs were constructed with the circRNA as a decoy, the miRNA as the core, and the mRNA as the target to construct a ceRNA regulatory network. The circRNA-ceRNA network pattern can show the regulation of the circRNA on the related mRNA-encoding genes.

Based on the RNA-seq data, we selected 11 dysregulated circRNAs, 7 dysregulated miRNAs and 8 dysregulated mRNAs, and there were 16 relationships contained in the constructed circRNA-miRNA-mRNA regulatory network (Figure 4 and Table 4). The ceRNA network covered two cases: one was circRNA (7 circRNAs upregulated in APP/PS1 mice)-miRNA (3 miRNAs downregulated in APP/PS1 mice)-mRNA (3 mRNAs upregulated in APP/PS1 mice), and the other was circRNA (4 circRNAs downregulated)-miRNA (4 miRNAs upregulated)-mRNA (5 mRNAs upregulated). These circRNA-miRNA-mRNA interactions may supply a novel perspective for the pathogenesis of AD. We observed that one circRNA could interact with different miRNAs and that one miRNA could be regulated by multiple circRNAs; for example, mmu_circ_0000717 could interact with mmu-miR-222-3p, mmu-miR-221-5p, mmu-miR-3102-3p and mmu-miR-344d-3-5p, and mmu-miR-298-3 could co-associate with mmu_circ_0001370, novel_circ_0007425, and novel_circ_0003012.

FIGURE 4.

FIGURE 4

CircRNA-ceRNA network analysis in hippocampal tissue of APP/PS1 Mice. The ceRNA networks were based on circRNA-miRNA and miRNA-mRNA interactions. Circle nodes represent circRNAs, triangle nodes represent miRNAs, and rectangle nodes represent mRNAs. Red represent upregulated, green represent downregulated. (A) circRNA (down in APP/PS1 mice)-miRNA (up in APP/PS1 mice)-mRNA (down in APP/PS1 mice). (B) circRNA (up in APP/PS1 mice)-miRNA (down in APP/PS1 mice)-mRNA (up in APP/PS1 mice).

TABLE 4.

CircRNA-ceRNA networks in AD.

CircRNA name MiRNA name Gene_id Gene name
mmu_circ_0001304 mmu-miR-296-3p ENSMUSG00000067288 Rps28
novel_circ_0001587 mmu-miR-296-3p ENSMUSG00000067288 Rps28
mmu_circ_0000672 mmu-miR-351-5p ENSMUSG00000068129 Cst7
mmu_circ_0001125 mmu-miR-351-5p ENSMUSG00000068129 Cst7
novel_circ_0003012 mmu-miR-298-3p ENSMUSG00000006179 Prss16
novel_circ_0007425 mmu-miR-298-3p ENSMUSG00000006179 Prss16
mmu_circ_0001370 mmu-miR-298-3p ENSMUSG00000006179 Prss16
mmu_circ_0000717 mmu-miR-3102-3p ENSMUSG00000029570 Lfng
mmu_circ_0000717 mmu-miR-221-5p ENSMUSG00000052688 Rab7b
mmu_circ_0000717 mmu-miR-344d-3-5p ENSMUSG00000040268 Plekha1
mmu_circ_0000717 mmu-miR-344d-3-5p ENSMUSG00000040298 Btbd16
novel_circ_0002029 mmu-miR-344d-3-5p ENSMUSG00000040268 Plekha1
novel_circ_0002029 mmu-miR-344d-3-5p ENSMUSG00000040298 Btbd16
mmu_circ_0000717 mmu-miR-222-3p ENSMUSG00000030711 Sult1a1
novel_circ_0005255 mmu-miR-222-3p ENSMUSG00000030711 Sult1a1
novel_circ_0001016 mmu-miR-222-3p ENSMUSG00000030711 Sult1a1

Verification of the Potential Regulatory Mechanism of circRNAs in the Key Signaling Pathways

Through KEGG analysis, we obtained key regulatory signaling pathways, including the cGMP-PKG signaling pathway, cAMP signaling pathway, and Hippo signaling pathway. These pathways have been reported to participate in key regulatory roles in neurodegenerative diseases.

We further explored the regulatory effects of the differential expression of circRNAs on the cGMP-PKG signaling pathway, cAMP signaling pathway, and Hippo signaling pathway. We searched for the differentially expressed circRNAs enriched in the 3 signaling pathways and obtained five circRNAs that might be involved in the cGMP-PKG signaling pathway: novel_circ_0002311, novel_circ_0009273, novel_circ_0003012, novel_circ_0003089, and novel_circ_0001331. Four circRNAs might be involved in the cAMP signaling pathway: novel_circ_0006299, novel_circ_0003012, novel_circ_0003089, and novel_circ_0001331. Two circRNAs might be involved in the Hippo signaling pathway: novel_circ_0008567 and mmu_circ_0000585.

We predicted differentially expressed miRNAs that interact with those circRNAs and found that novel_circ_0009273, novel_circ_0003012, novel_circ_0006299, novel_circ_0008567, and mmu_circ_0000585 could target mmu-miR-3074-1-3p, mmu-miR-298-3p, mmu-miR-296-3p, mmu-miR-298-5p, mmu-miR-3074-1-3p, and mmu-miR-669e-5p, respectively.

Through the predictive analysis of miRNA-mRNA interactions, we identified the downstream target mRNAs that might be regulated and constructed a circRNA-ceRNA network related to the three signaling pathways (Figure 5A and Table 5). Based on the regulatory mechanism of circRNA-ceRNA, we ultimately screened the novel_circ_0003012/mmu-miR-298-3p/Smoc2 signaling axis, which might affect the cGMP-PKG signaling pathway (Figure 5B). We used qPCR to verify the differential expression of these genes, and used WB to verify the level of Smoc2, the results are shown in Figures 5C,D.

FIGURE 5.

FIGURE 5

Verification of the potential regulation mechanism of circRNAs in the key signaling pathways. (A) CircRNA-ceRNA network of circRNAs in the key signaling pathways. Circle nodes represent circRNAs, triangle nodes represent miRNAs, and rectangle nodes represent mRNAs. Red represent upregulated, green represent downregulated. (B) The interaction of novel_circ_0003012/mmu-miR-298-3p. (C) The expression levels of novel_circ_0003012, mmu-miR-298-3p and SMOC2 by qPCR in hippocampal tissues of 8-month-old APP/PS1 mice and WT mice. CircRNA and mRNA expression was quantified relative to Gapdh expression level by using the comparative cycle threshold (ΔCT) method. MiRNA expression was quantified relative to U6 expression level by using the comparative cycle threshold (ΔCT) method. Data are presented as means ± SD (n = 6; *p < 0.05). (D) The expression of Smoc2 by Western blot in hippocampal tissues of 8-month-old APP/PS1 mice and WT mice. Data are presented as means ± SD (n = 2). (E) The expression of PKG by Western blot in hippocampal tissues of 8-month-old APP/PS1 mice and WT mice. Data are presented as means ± SD (n = 3; *p < 0.05).

TABLE 5.

CircRNA-ceRNA networks in cGMP-PKG, cAMP, and Hippo signaling pathway.

CircRNA name MiRNA name Gene_id Gene name
novel_circ_0009273 mmu-miR-3074-1-3p ENSMUSG00000031486 Adgra2
novel_circ_0003012 mmu-miR-298-3p ENSMUSG00000023886 Smoc2
novel_circ_0006299 mmu-miR-296-3p ENSMUSG00000026825 Dnm1
novel_circ_0006299 mmu-miR-296-3p ENSMUSG00000046854 Pip5kl1
novel_circ_0006299 mmu-miR-296-3p ENSMUSG00000004789 Dlst
novel_circ_0006299 mmu-miR-296-3p ENSMUSG00000023886 Smoc2
novel_circ_0006299 mmu-miR-296-3p ENSMUSG00000024969 Mark2
novel_circ_0006299 mmu-miR-296-3p ENSMUSG00000042632 Pla2g6
novel_circ_0008567 mmu-miR-298-5p ENSMUSG00000028931 Kcnab2
novel_circ_0008567 mmu-miR-298-5p ENSMUSG00000024942 Capn1
novel_circ_0008567 mmu-miR-298-5p ENSMUSG00000031169 Porcn
novel_circ_0008567 mmu-miR-298-5p ENSMUSG00000020532 Acaca
novel_circ_0008567 mmu-miR-298-5p ENSMUSG00000028801 Stpg1
novel_circ_0008567 mmu-miR-298-5p ENSMUSG00000005936 Kctd20
novel_circ_0008567 mmu-miR-298-5p ENSMUSG00000023886 Smoc2
novel_circ_0008567 mmu-miR-298-5p ENSMUSG00000022377 Asap1
novel_circ_0008567 mmu-miR-298-5p ENSMUSG00000015766 Eps8
mmu_circ_0000585 mmu-miR-3074-1-3p ENSMUSG00000031486 Adgra2

Furthermore, we also verified whether the circRNA-ceRNA network affects the cGMP-PKG signaling pathway. As shown in Figure 5E, we used Western blotting to detect the expression of PKG, a key factor in the cGMP-PKG signaling pathway, and the results showed that the expression of PKG in the hippocampus of APP/PS1 mice was significantly reduced compared with that in the WT group (p < 0.05).

Preliminary verification of the regulatory role of the novel_circ_0003012/mmu-miR-298-3p/Smoc2 signaling axis in the pathology of AD showed that it involved the downregulation of PKG.

Discussion

Analyzing the expression profiles of circRNA-ceRNA may provide new insights into our understanding of the pathophysiology of AD. In our study, we found 70 dysregulated circRNAs, 39 dysregulated miRNAs and 121 dysregulated mRNA between the APP/PS1 group and wild-type group at 8 months in the hippocampus of the mice; 44 circRNAs, 16 miRNAs and 34 mRNAs were upregulated, and 26 circRNAs, 23 miRNAs, and 87 mRNAs were downregulated in APP/PS1 mice relative to their levels in wild-type mice. Through correlation analysis, we obtained 11 dysregulated circRNAs (7 upregulated circRNAs and 4 downregulated), 7 dysregulated miRNAs (4 upregulated miRNAs and 3 downregulated) and 8 dysregulated mRNAs (3 upregulated mRNAs and 5 downregulated), forming 16 relationships in the circRNA-miRNA-mRNA regulatory network. Our results showed that the aberrantly expressed circRNAs had miRNA-binding sites and were thus predicted to play a regulatory role via the ceRNA mechanism (Zhang et al., 2020). These circRNA-miRNA-mRNA regulatory networks may play an important role in the onset and development of AD. For instance, mmu_circ_0001125 and mmu_circ_0000672 were found to be ceRNAs of mmu-miR-351-5p, which targets Cst7 (ENSMUSG00000068129). Cst7 (cystatin F) encodes an endosomal/lysosomal cathepsin inhibitor that regulates cathepsin activity in the lysosomal pathway (Magister and Kos, 2013). The expression of Cst7 is important in microglia for reducing the phagocytic capacity of activated microglia. Reducing the expression of Cst7 might promote the clearance of Aβ species through microglia and macrophages (Ofengeim et al., 2017).

The GO analysis was performed to further annotate the biological functions related to the aberrantly expressed circRNAs. The top GO terms of the differentially expressed circRNAs were most enriched in biological metabolic processes, such as phosphorus metabolic process, organophosphate metabolic process, nucleotide metabolic process, nucleoside phosphate metabolic process, pyrimidine nucleobase metabolic process, ribonucleotide metabolic process and ribose phosphate metabolic process. This result indicated that the pathological progression of AD may be associated with several metabolic pathways regulated by circRNAs. In addition, we also performed GO analysis of miRNAs and mRNAs. The top terms of miRNAs were almost all associated with cellular metabolic process, intracellular organelle/part and binding functions. The dysregulated mRNAs were mostly enriched in cellular/organism development processes or cell differentiation.

As the main components of nucleic acids, nucleobases, nucleosides, nucleotides and related phosphorylated metabolites have many important roles as intermediates in biosynthetic pathways in biological systems (Lane and Fan, 2015; Swerdlow, 2018; Muguruma et al., 2020). There is growing evidence that nucleotide metabolism is involved in pathological mechanisms in many different neurodegenerative diseases, such as Alzheimer’s disease. As Gonzalez-Dominguez et al. (2015) revealed, numerous metabolites, including purine and pyrimidine metabolites, show significant differences between AD and WT mice in all brain tissues, especially in hippocampal and cortical regions. This result indicated that alterations in the metabolism of nucleotides play an important role in the pathological process of AD. For instance, purinergic signaling plays a critical role in the development of AD. Studies have demonstrated that adenosine receptors in the frontal cortex of the affected brain are upregulated and that these receptors are redistributed. Furthermore, these receptors have higher activity in neurons affected by Aβ deposition (Albasanz et al., 2008; Cieslak and Wojtczak, 2018).

In addition, abnormal synthesis or metabolism of pyrimidine nucleotides is also considered to be an important factor in the pathological process of AD, and its disorder can cause dysfunction of the oxidative phosphorylation (OXPHOS) system (Pesini et al., 2019). The OXPHOS system plays an important role in the mechanism of synaptic failure and neurodegeneration triggered by Aβ (Pesini et al., 2014). After Aβ deposition, OXPHOS dysfunction appears to be a frequent finding in many AD patients (Swerdlow et al., 2014). OXPHOS participates in many cellular processes, and defects in this system affect many biochemical pathways. One of these biochemical pathways is de novo pyrimidine biosynthesis. A decrease in the de novo synthesis of pyrimidine nucleotides leads to dysfunction of the OXPHOS system and to the pathogenesis of late-onset AD (Pesini et al., 2019). Disorders of pyrimidine metabolism, with decreased uridine monophosphate and increased uracil, ultimately lead to synaptic plasticity and neuronal impairment (Czech et al., 2012). Several studies have also indicated that oxidative stress is closely related to the abnormal metabolism of purines and pyrimidines in AD (Lyras et al., 1997; Gonzalez-Dominguez et al., 2015). All these results indicate that abnormal nucleotide metabolism is also an important factor in the onset and development of AD. These circRNAs in the hippocampus of AD mice may play a critical role in the pathological progression of AD by regulating nucleotide metabolism.

Kyoto Encyclopedia of Genes and Genomes analysis showed that the dysregulation of circRNAs was enriched in many signaling pathways, which are closely related to the pathogenesis of AD, including the cGMP-PKG signaling pathway, cAMP signaling pathway, Hippo signaling pathway, platelet activation, LTP and axon guidance. KEGG pathway analysis of dysregulated miRNAs and mRNAs also identified enrichment in focal adhesion, axon guidance, platelet activation and the Hippo signaling pathway. In particular, the signaling pathways of miRNA and mRNA enrichment, such as platelet activation, axon guidance and the Hippo signaling pathway, were consistent with the KEGG analysis of circRNAs.

Other studies have also reported that several dysregulated circRNAs in the cerebral cortex of AD mice are enriched in the PI3K-Akt signaling pathway, tight junctions, Hippo signaling pathway, LTP and axon guidance (Zhang et al., 2017; Ma et al., 2019). These results are consistent with our study that the dysregulated circRNAs in the hippocampus of AD mice were also enriched in the Hippo signaling pathway, LTP and axon guidance. The Hippo signaling pathway, also known as the Salvador/Warts/Hippo (SWH) pathway, is named after the protein kinase Hippo (Hpo) in Drosophila and is a key regulator in the pathway (Zheng and Pan, 2019). The Hippo pathway is composed of a series of conserved kinases (Huang et al., 2005). Numerous studies have confirmed that the Hippo signaling pathway plays an important role in cell functions. Hippo signaling activates induced cell death, whereas inactivation of Hippo signaling triggers cell proliferation (Grusche et al., 2011; Sun and Irvine, 2011). A recent study indicated that the Hippo pathway plays an important role in the pathogenesis of AD. The Hippo pathway affects Aβ42-mediated neurodegeneration due to the excessive activation of Hippo signaling, leading to enhanced Aβ42 toxicity; however, downregulation of the Hippo signaling pathway can rescue Aβ42-mediated neurodegeneration (Irwin et al., 2020).

Interestingly, we also found that the signaling pathways of the cGMP-PKG signaling pathway, cAMP signaling pathway and platelet activation in the hippocampus of AD mice were associated with dysregulated circRNAs in the pathogenesis of AD (Kelly, 2018; Ricciarelli and Fedele, 2018). Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) are well-established second messengers required for LTP and memory formation and consolidation (Ricciarelli and Fedele, 2018). Recent evidence indicates that excessive Aβ deposition inhibits both the cAMP and cGMP pathways and impairs LTP signal transduction. Changes in cAMP signals in specific brain regions may be related to the pathology of dementia. Reduced cAMP signaling is an important factor in AD pathology. Increasing cAMP signaling in specific regions of the brain can resist age-related declines in brain function. Studies have shown that cAMP levels in the hippocampus can be reduced by the overexpression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) or the infusion of Aβ142 (Chen et al., 2012; Zhang et al., 2014). Furthermore, cAMP-elevating agents can reverse or prevent Aβ-induced hippocampal deficits.

Cyclic guanosine monophosphate-dependent protein kinase (PKG) and the cGMP controller phosphodiesterase are critical participants in the neuroinflammatory process, which may lead to neurological dysfunction, cell death and further neurodegeneration (Ricciarelli and Fedele, 2018). The increase in cGMP levels decreases the Aβ load in transgenic models of AD and in models of physiological aging (Sierksma et al., 2013). In addition, cGMP-dependent Akt activation and GSK3β inactivation can reduce tau hyperphosphorylation. PKG, as the key downstream target of cGMP, has been reported to be significantly decreased in both the cortex and hippocampus after treatment with Aβ (Wang et al., 2017). The cGMP-PKG pathway plays a crucial role in preventing apoptosis and promoting neural cell survival. It has been shown that the activation of PKG in hippocampal neurons is involved in the LTP induced by NO and carbon monoxide (Fiscus, 2002). Inhibition of PKG activity in hippocampal neurons can partially block the prosurvival effects of APPS, suggesting that cGMP, via activation of PKG, mediates the neuroprotective effect of APPS (Barger et al., 1995; Fiscus, 2002). Our results are consistent with the above research, confirming that the expression of PKG in the hippocampus was obviously decreased in AD mice and that the cGMP-PKG pathway might play an essential role in the pathophysiology of AD.

From the results of the circRNA-ceRNA network constructed on the basis of the differentially expressed circRNAs, miRNAs and mRNAs obtained from the sequencing analysis results and the series of circRNAs predicted by KEGG analysis that are closely related to the cGPM-PKG signaling pathway, we found that the novel_circ_0003012/mmu-miR-298-3p/Smoc2 signaling axis may be closely related to the pathological mechanism of AD.

Through preliminary verification, we found that the differential expression of novel_circ_0003012 and mmu-miR-298-3p may regulate the pathological mechanism of AD by affecting the cGPM-PKG signaling pathway.

Conclusion

In summary, we elucidated the circRNA-ceRNA network patterns in the hippocampus of APP/PS1 and WT mice by using deep RNA-seq analysis. Our findings further expand the current knowledge regarding the biology of circRNA-ceRNA, their involved signaling pathways, such as the dysregulated circRNAs in nucleotide metabolism, cGMP-PKG signaling pathway, cAMP signaling pathway, platelet activation and Hippo signaling pathway, and their regulatory roles in AD pathogenesis. In addition, our findings preliminarily verified that the novel_circ_0003012/mmu-miR-298-3p/Smoc2 signaling axis may regulate the pathophysiology of AD by affecting the cGMP-PKG signaling pathway. These newly identified circRNAs in networks and signaling pathways reveal potential diagnostic or therapeutic targets for AD.

Data Availability Statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA712946.

Ethics Statement

The animal study was reviewed and approved by Medical Ethics Committee of Qingdao University.

Author Contributions

YZ conceived and wrote the manuscript. YZ and LQ reviewed and edited the manuscript. YLy, YLg, WY, and YZf participatedin literature search, data collection, and figures design. All authors read and approved the manuscript.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Abbreviations

AD

Alzheimer’s disease

BACE1

β-site amyloid precursor protein-cleaving enzyme 1

BP

biological process

cAMP

cyclic adenosine monophosphate

CC

cellular component

ceRNAs

competitive endogenous RNAs

circRNAs

circular RNAs

cGMP

cyclic guanosine monophosphate

Cst7

cystatin F

GO

Gene ontology

KEGG

Kyoto Encyclopedia of Genes and Genomes

LTP

long-term potentiation

MF

molecular function

MREs

miRNA response elements

OXPHOS

oxidative phosphorylation

PKG

cGMP-dependent protein kinase

WT

wild-type.

Funding. This work was supported by funding from the National Natural Science Foundation of China (No. 81901085), the China Postdoctoral Science Foundation (No. 2019M662302), and the Qingdao Applied Basic Research Project (No. 19-6-2-50-cg).

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnmol.2021.665788/full#supplementary-material

References

  1. Albasanz J. L., Perez S., Barrachina M., Ferrer I., Martin M. (2008). Up-regulation of adenosine receptors in the frontal cortex in Alzheimer’s disease. Brain Pathol. 18 211–219. 10.1111/j.1750-3639.2007.00112.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barger S. W., Fiscus R. R., Ruth P., Hofmann F., Mattson M. P. (1995). Role of cyclic GMP in the regulation of neuronal calcium and survival by secreted forms of beta-amyloid precursor. J. Neurochem. 64 2087–2096. 10.1046/j.1471-4159.1995.64052087.x [DOI] [PubMed] [Google Scholar]
  3. Chen Y., Huang X., Zhang Y. W., Rockenstein E., Bu G., Golde T. E., et al. (2012). Alzheimer’s beta-secretase (BACE1) regulates the cAMP/PKA/CREB pathway independently of beta-amyloid. J. Neurosci. 32 11390–11395. 10.1523/jneurosci.0757-12.2012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cieslak M., Wojtczak A. (2018). Role of purinergic receptors in the Alzheimer’s disease. Purinergic Signal. 14 331–344. 10.1007/s11302-018-9629-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Czech C., Berndt P., Busch K., Schmitz O., Wiemer J., Most V., et al. (2012). Metabolite profiling of Alzheimer’s disease cerebrospinal fluid. PLoS One 7:e31501. 10.1371/journal.pone.0031501 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. D’Ambra E., Capauto D., Morlando M. (2019). Exploring the regulatory role of circular RNAs in Neurodegenerative Disorders. Int. J. Mol. Sci. 20:5477. 10.3390/ijms20215477 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fiscus R. R. (2002). Involvement of cyclic GMP and protein kinase G in the regulation of apoptosis and survival in neural cells. Neuro Signals 11 175–190. 10.1159/000065431 [DOI] [PubMed] [Google Scholar]
  8. Gao Y., Wang J., Zhao F. (2015). CIRI: an efficient and unbiased algorithm for de novo circular RNA identification. Genome Biol. 16:4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gonzalez-Dominguez R., Garcia-Barrera T., Vitorica J., Gomez-Ariza J. L. (2015). Metabolomic screening of regional brain alterations in the APP/PS1 transgenic model of Alzheimer’s disease by direct infusion mass spectrometry. J. Pharm. Biomed. Anal. 102 425–435. 10.1016/j.jpba.2014.10.009 [DOI] [PubMed] [Google Scholar]
  10. Gouras G. K., Olsson T. T., Hansson O. (2015). beta-Amyloid peptides and amyloid plaques in Alzheimer’s disease. Neurotherapeutics 12 3–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Grusche F. A., Degoutin J. L., Richardson H. E., Harvey K. F. (2011). The Salvador/Warts/Hippo pathway controls regenerative tissue growth in Drosophila melanogaster. Dev. Biol. 350 255–266. 10.1016/j.ydbio.2010.11.020 [DOI] [PubMed] [Google Scholar]
  12. Huang J., Wu S., Barrera J., Matthews K., Pan D. (2005). The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 122 421–434. 10.1016/j.cell.2005.06.007 [DOI] [PubMed] [Google Scholar]
  13. Huang J. L., Qin M. C., Zhou Y., Xu Z. H., Yang S. M., Zhang F., et al. (2018). Comprehensive analysis of differentially expressed profiles of Alzheimer’s disease associated circular RNAs in an Alzheimer’s disease mouse model. Aging 10 253–265. 10.18632/aging.101387 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Irwin M., Tare M., Singh A., Puli O. R., Gogia N., Riccetti M., et al. (2020). A positive feedback loop of Hippo- and c-Jun-Amino-terminal kinase signaling pathways regulates amyloid-beta-mediated Neurodegeneration. Front. Cell Dev. Biol. 8:117. 10.3389/fcell.2020.00117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kelly M. P. (2018). Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain. Cell. Signal. 42 281–291. 10.1016/j.cellsig.2017.11.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kristensen L. S., Andersen M. S., Stagsted L. V. W., Ebbesen K. K., Hansen T. B., Kjems J. (2019). The biogenesis, biology and characterization of circular RNAs. Nat. Rev. Genet. 20 675–691. [DOI] [PubMed] [Google Scholar]
  17. Lane A. N., Fan T. W. (2015). Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res. 43 2466–2485. 10.1093/nar/gkv047 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lazarov O., Marr R. A. (2010). Neurogenesis and Alzheimer’s disease: at the crossroads. Exp. Neurol. 223 267–281. 10.1016/j.expneurol.2009.08.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lei K., Bai H., Wei Z., Xie C., Wang J., Li J., et al. (2018). The mechanism and function of circular RNAs in human diseases. Exp. Cell Res. 368 147–158. 10.1016/j.yexcr.2018.05.002 [DOI] [PubMed] [Google Scholar]
  20. Lyras L., Cairns N. J., Jenner A., Jenner P., Halliwell B. (1997). An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer’s disease. J, Neurochem. 68 2061–2069. 10.1046/j.1471-4159.1997.68052061.x [DOI] [PubMed] [Google Scholar]
  21. Ma N., Pan J., Ye X., Yu B., Zhang W., Wan J. (2019). Whole-transcriptome analysis of APP/PS1 mouse brain and identification of circRNA-miRNA-mRNA networks to investigate AD pathogenesis. Mol. Ther. Nucleic Acids 18 1049–1062. 10.1016/j.omtn.2019.10.030 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Magister S., Kos J. (2013). Cystatins in immune system. J. Cancer 4 45–56. 10.7150/jca.5044 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Matsuzaki M., Honkura N., Ellis-Davies G. C., Kasai H. (2004). Structural basis of long-term potentiation in single dendritic spines. Nature 429 761–766. 10.1038/nature02617 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Memczak S., Jens M., Elefsinioti A., Torti F., Krueger J., Rybak A., et al. (2013). Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495 333–338. 10.1038/nature11928 [DOI] [PubMed] [Google Scholar]
  25. Mu Y., Gage F. H. (2011). Adult hippocampal neurogenesis and its role in Alzheimer’s disease. Mol. Neurodegener. 6:85. 10.1186/1750-1326-6-85 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Muguruma Y., Tsutsui H., Akatsu H., Inoue K. (2020). Comprehensive quantification of purine and pyrimidine metabolism in Alzheimer’s disease postmortem cerebrospinal fluid by LC-MS/MS with metal-free column. Biomed. Chromatogra. 34:e4722. 10.1002/bmc.4722 [DOI] [PubMed] [Google Scholar]
  27. Ofengeim D., Mazzitelli S., Ito Y., DeWitt J. P., Mifflin L., Zou C., et al. (2017). RIPK1 mediates a disease-associated microglial response in Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 114 E8788–E8797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Pertea M., Kim D., Pertea G. M., Leek J. T., Salzberg S. L. (2016). Transcript-level expression analysis of RNA-seq experiments with HISAT. StringTie and Ballgown. Nat. Protoc. 11 1650–1667. 10.1038/nprot.2016.095 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Pesini A., Iglesias E., Bayona-Bafaluy M. P., Garrido-Perez N., Meade P., Gaudo P., et al. (2019). Brain pyrimidine nucleotide synthesis and Alzheimer disease. Aging 11 8433–8462. 10.18632/aging.102328 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Pesini A., Iglesias E., Garrido N., Bayona-Bafaluy M. P., Montoya J., Ruiz-Pesini E. (2014). OXPHOS, pyrimidine nucleotides, and Alzheimer’s disease: a pharmacogenomics approach. J. Alzheimer’s Dis 42 87–96. 10.3233/jad-140384 [DOI] [PubMed] [Google Scholar]
  31. Ricciarelli R., Fedele E. (2018). cAMP, cGMP and amyloid beta: three ideal partners for memory formation. Trends Neurosci. 41 255–266. 10.1016/j.tins.2018.02.001 [DOI] [PubMed] [Google Scholar]
  32. Sierksma A. S., Rutten K., Sydlik S., Rostamian S., Steinbusch H. W., van den Hove D. L., et al. (2013). Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer’s disease. Neuropharmacology 64 124–136. 10.1016/j.neuropharm.2012.06.048 [DOI] [PubMed] [Google Scholar]
  33. Sun G., Irvine K. D. (2011). Regulation of Hippo signaling by Jun kinase signaling during compensatory cell proliferation and regeneration, and in neoplastic tumors. Dev. Biol. 350 139–151. 10.1016/j.ydbio.2010.11.036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Swerdlow R. H. (2018). Mitochondria and mitochondrial cascades in Alzheimer’s Disease. J. Alzheimer’s Dis 62 1403–1416. 10.3233/jad-170585 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Swerdlow R. H., Burns J. M., Khan S. M. (2014). The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives. Biochim. Biophys. Acta 1842 1219–1231. 10.1016/j.bbadis.2013.09.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Tiwari S., Atluri V., Kaushik A., Yndart A., Nair M. (2019). Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. Int. J. Nanomed. 14 5541–5554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Wang J. Z., Wang Z. H., Tian Q. (2014). Tau hyperphosphorylation induces apoptotic escape and triggers neurodegeneration in Alzheimer’s disease. Neurosci. Bull. 30 359–366. 10.1007/s12264-013-1415-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Wang L., Xiaokaiti Y., Wang G., Xu X., Chen L., Huang X., et al. (2017). Inhibition of PDE2 reverses beta amyloid induced memory impairment through regulation of PKA/PKG-dependent neuro-inflammatory and apoptotic pathways. Sci. Rep. 7:12044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Wang Z., Xu P., Chen B., Zhang Z., Zhang C., Zhan Q., et al. (2018). Identifying circRNA-associated-ceRNA networks in the hippocampus of Abeta1-42-induced Alzheimer’s disease-like rats using microarray analysis. Aging 10 775–788. 10.18632/aging.101427 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Wilkins H. M., Swerdlow R. H. (2017). Amyloid precursor protein processing and bioenergetics. Brain Res. Bull. 133 71–79. 10.1016/j.brainresbull.2016.08.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Zhang C., Cheng Y., Wang H., Wang C., Wilson S. P., Xu J., et al. (2014). RNA interference-mediated knockdown of long-form phosphodiesterase-4D (PDE4D) enzyme reverses amyloid-beta42-induced memory deficits in mice. J. Alzheimer’s Dis 38 269–280. 10.3233/jad-122236 [DOI] [PubMed] [Google Scholar]
  42. Zhang L., Ding H., Zhang Y., Wang Y., Zhu W., Li P. (2020). Circulating MicroRNAs: biogenesis and clinical significance in acute myocardial infarction. Front. Physiol. 11:1088. 10.3389/fphys.2020.01088 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Zhang S., Zhu D., Li H., Li H., Feng C., Zhang W. (2017). Characterization of circRNA-Associated-ceRNA networks in a senescence-accelerated mouse prone 8 brain. Mol. Ther. 25 2053–2061. 10.1016/j.ymthe.2017.06.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Zheng Y., Pan D. (2019). The hippo signaling pathway in development and disease. Dev. Cell 50 264–282. 10.1016/j.devcel.2019.06.003 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Data Availability Statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA712946.


Articles from Frontiers in Molecular Neuroscience are provided here courtesy of Frontiers Media SA

RESOURCES